1. Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy
   Zachary J. Walker et al, 2021, Clinical Cancer Research CrossRef
2. Mesenchymal stem cells secretomes' affect multiple myeloma translation initiation
   H. Marcus et al, 2016, Cellular Signalling CrossRef
3. Multiple myeloma and bone marrow mesenchymal stem cells’ crosstalk: Effect on translation initiation
   Oshrat Attar-Schneider et al, 2016, Molecular Carcinogenesis CrossRef
4. Migration and epithelial-to-mesenchymal transition of lung cancer can be targeted via translation initiation factors eIF4E and eIF4GI
   Oshrat Attar-Schneider et al, 2016, Laboratory Investigation CrossRef
5. eIF4E and eIF4GI have distinct and differential imprints on multiple myeloma's proteome and signaling
   Oshrat Attar-Schneider et al, 2015, Oncotarget CrossRef
6. Cell Fate Control by Translation: mRNA Translation Initiation as a Therapeutic Target for Cancer Development and Stem Cell Fate Control
   Hyun-Jung Kim, 2019, Biomolecules CrossRef
7. The Autophagy-Lysosomal Pathways and Their Emerging Roles in Modulating Proteostasis in Tumors
   Zhen Dong et al, 2018, Cells CrossRef
8. Targeting the ribosome to treat multiple myeloma
   Kylee H. Maclachlan et al, 2024, Molecular Therapy: Oncology CrossRef
9. Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis
   Inge Oudaert et al, 2022, Journal of Experimental & Clinical Cancer Research CrossRef
10. The Cap-Binding Complex CBC and the Eukaryotic Translation Factor eIF4E: Co-Conspirators in Cap-Dependent RNA Maturation and Translation
    Jean-Clement Mars et al, 2021, Cancers CrossRef
11. The mitochondrial pyruvate carrier complex potentiates the efficacy of proteasome inhibitors in multiple myeloma
    Steven Findlay et al, 2023, Blood Advances CrossRef
12. A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement
    Leo Rasche et al, 2016, Clinical Cancer Research CrossRef
13. Feature-weighted ordinal classification for predicting drug response in multiple myeloma
    Ziyang Ma et al, 2021, Bioinformatics CrossRef
14. Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine
    Sarit Assouline et al, 2023, Haematologica CrossRef
15. Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapy
    Yanmeng Wang et al, 2024, Cell Communication and Signaling CrossRef
16. Pterostilbene inhibits nutrient metabolism and induces apoptosis through AMPK activation in multiple myeloma cells
    Huiling Mei et al, 2018, International Journal of Molecular Medicine CrossRef
17. Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma
    Shirong Li et al, 2016, Molecular Cancer Therapeutics CrossRef
18. Build-UPS and break-downs: metabolism impacts on proteostasis and aging
    Franziska Ottens et al, 2021, Cell Death & Differentiation CrossRef
19. Multiple myeloma BM-MSCs increase the tumorigenicity of MM cells via transfer of VLA4-enriched microvesicles
    Mahmoud Dabbah et al, 2020, Carcinogenesis CrossRef
20. BM-MSCs-derived ECM modifies multiple myeloma phenotype and drug response in a source-dependent manner
    Amjd Ibraheem et al, 2019, Translational Research CrossRef
21. Noncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming
    Irene Riz et al, 2016, Oncotarget CrossRef